Ajanta Pharma Limited

AJANTPHARM

INE031B01049

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:13:51 31/05/2024 pm IST			5-day change	1st Jan Change
2,333 ^INR	-3.27%		-3.69%	+11.97%

03/05	INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh	RE
02/05	Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4	MT

Ajanta Pharma Limited Announces Resignation of Purushottam B. Agrawal, Director of the Company

March 27, 2019 at 11:28 pm IST

Ajanta Pharma Limited announced resignation of Mr. Purushottam B. Agrawal, Director of the Company.

Latest news about Ajanta Pharma Limited

INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh	03/05	RE
Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4	02/05	MT
Ajanta Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	02/05	CI
Ajanta Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024	02/05	CI
Ajanta Pharma Limited announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.	02/05	CI
Ajanta Pharma Limited Provides Revenue Guidance for the Fiscal Year 2025	02/05	CI
Transcript : Ajanta Pharma Limited, Q4 2024 Earnings Call, May 02, 2024	02/05
Ajanta Pharma Limited authorizes a Buyback Plan.	02/05	CI
Ajanta Pharma Limited?s Board intends to launch an Equity Buyback on May 2, 2024.	26/04	CI
Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit	02/02	MT
Transcript : Ajanta Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024	31/01
Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024	31/01	CI
Ajanta Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	31/01	CI
Ajanta Pharma Board to Consider Second Interim Dividend for Fiscal 2024	25/01	MT
Ajanta Pharma Limited Provides Earnings Guidance for the Full Year of Fiscal 2024	31/23/31	CI
Transcript : Ajanta Pharma Limited, Q2 2024 Earnings Call, Oct 31, 2023	31/23/31
Ajanta Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	31/23/31	CI
Ajanta Pharma Gets US FDA Nod for Topiramate Extended-Release Capsules	31/23/31	MT
Ajanta Pharma Limited Receives Final Approval from US FDA for Topiram Extended Release Capsules	30/23/30	CI
Ajanta Pharma Logs Increase in Fiscal Q1 Consolidated Profit	28/23/28	MT
Transcript : Ajanta Pharma Limited, Q1 2024 Earnings Call, Jul 27, 2023	27/23/27
Ajanta Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	27/23/27	CI
Ajanta Pharma Board to Consider Interim Dividend for Fiscal 2024	24/23/24	MT
Ajanta Pharma Limited Confirms the Interim Dividend for the Year Ended 31 March 2023	18/23/18	CI
Ajanta Pharma Gets No Observations After US FDA's Inspection of API Facility in Hyderabad, India	26/23/26	MT

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ajanta Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,333 INR

Average target price

2,440 INR

Spread / Average Target

+4.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
AJANTA PHARMA LIMITED	+11.97%	3.49B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals